Afonso, J.; Gonçalves, C.; Costa, M.; Ferreira, D.; Santos, L.; Longatto-Filho, A.; Baltazar, F.
Glucose Metabolism Reprogramming in Bladder Cancer: Hexokinase 2 (HK2) as Prognostic Biomarker and Target for Bladder Cancer Therapy. Cancers 2023, 15, 982.
https://doi.org/10.3390/cancers15030982
AMA Style
Afonso J, Gonçalves C, Costa M, Ferreira D, Santos L, Longatto-Filho A, Baltazar F.
Glucose Metabolism Reprogramming in Bladder Cancer: Hexokinase 2 (HK2) as Prognostic Biomarker and Target for Bladder Cancer Therapy. Cancers. 2023; 15(3):982.
https://doi.org/10.3390/cancers15030982
Chicago/Turabian Style
Afonso, Julieta, Céline Gonçalves, Marta Costa, Débora Ferreira, Lúcio Santos, Adhemar Longatto-Filho, and Fátima Baltazar.
2023. "Glucose Metabolism Reprogramming in Bladder Cancer: Hexokinase 2 (HK2) as Prognostic Biomarker and Target for Bladder Cancer Therapy" Cancers 15, no. 3: 982.
https://doi.org/10.3390/cancers15030982
APA Style
Afonso, J., Gonçalves, C., Costa, M., Ferreira, D., Santos, L., Longatto-Filho, A., & Baltazar, F.
(2023). Glucose Metabolism Reprogramming in Bladder Cancer: Hexokinase 2 (HK2) as Prognostic Biomarker and Target for Bladder Cancer Therapy. Cancers, 15(3), 982.
https://doi.org/10.3390/cancers15030982